A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Latest Information Update: 14 Jun 2023
At a glance
- Drugs Perampanel (Primary)
- Indications Absence epilepsy; Complex partial epilepsy; Epilepsy; Generalised seizures; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
- Focus Therapeutic Use
- Acronyms PROVE; Study 506
- Sponsors Eisai Inc
- 27 Apr 2023 Results of pooled analysis of PERMIT and PROVE assessing perampanel when used in everyday clinical practice, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 20 Apr 2023 According to a Catalyst Pharmaceuticals media release, abstract will be presented at the upcoming AAN 2023 Annual Meeting taking place in Boston, MA and virtually on April 22-27, 2023.
- 20 Apr 2023 According to a Catalyst Pharmaceuticals media release, data from this study (to be presented in AAN 2023) is presented online https://index.mirasmart.com/aan2023/PDFfiles/AAN2023-002293.html.